SCHEMBL22856482

SCHEMBL22856482

CCCOC1CCN(CC(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.43
PIK3CD O00329 2/20 0.36
NPC1 O15118 1/20 0.36
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CYP2D6 P10635 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
HRH2 P25021 1/20 0.32
HRH1 P35367 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
NAMPT P43490 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22526539 0.89 HRH3 (0.44) HRH3PIK3CDNPC1CARM1PRMT6
SCHEMBL25162897 0.88 HRH3 (0.40) HRH3PIK3CDNPC1CARM1PRMT6
SCHEMBL22837708 0.85 HRH3 (0.43) HRH3PIK3CDNPC1CARM1PRMT6
SCHEMBL22477387 0.85 HRH3 (0.45) HRH3PIK3CDCARM1PRMT6TSHR
SCHEMBL25701241 0.83 HRH3 (0.40) HRH3PIK3CDNPC1CARM1PRMT6
SCHEMBL20325134 0.82 NPC1 (0.42) HRH3NPC1CARM1PRMT6NAMPT
SCHEMBL22856352 0.82 HRH3 (0.41) HRH3PIK3CDNPC1CARM1PRMT6
SCHEMBL18782650 0.81 PIK3CD (0.42) PIK3CDCHRM2CHRM1
SCHEMBL24764910 0.81 HRH3 (0.40) HRH3PIK3CDNPC1CARM1PRMT6
SCHEMBL23568260 0.81 HRH3 (0.40) HRH3PIK3CDNPC1CARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-22 US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 WO disclosed
WO-2022125790-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HRH3 3631/4885PIK3CD 321/4885NPC1 3159/4885
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HRH3 3631/4885PIK3CD 321/4885NPC1 3159/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HRH3 3631/4885PIK3CD 321/4885NPC1 3159/4885
US-11707457-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HRH3 3631/4885PIK3CD 321/4885NPC1 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.